<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23694">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798328</url>
  </required_header>
  <id_info>
    <org_study_id>TP-CLN-100394</org_study_id>
    <nct_id>NCT02798328</nct_id>
  </id_info>
  <brief_title>Direct Oral Anticoagulant Assay Detection &amp; Classification Study for the TEG 6S System</brief_title>
  <official_title>Direct Oral Anticoagulant Assay Detection &amp; Classification Study for the TEG 6S System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haemonetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haemonetics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational trial to evaluate the effectiveness of the TEG6s DOAC cartridge to detect and
      classify the presence of DOAC drugs in a subject.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence / Absence of DOAC Drug</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">395</enrollment>
  <condition>DOAC Eligible Subjects</condition>
  <arm_group>
    <arm_group_label>Reference Range</arm_group_label>
    <description>Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOAC Pivotal</arm_group_label>
    <description>DOAC Eligible Subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TEG6s DOAC Cartridge</intervention_name>
    <description>Testing subjects for presence of DOAC</description>
    <arm_group_label>Reference Range</arm_group_label>
    <arm_group_label>DOAC Pivotal</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        DOAC Eligible Subjects
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 18 years old

          -  DOAC administered for a minimum of 7 days

        Exclusion Criteria:

          -  Genetic Bleeding disorders. Known or subsequently discovered inherited defects of
             coagulation (e.g. hemophilia or Von Willebrand disease)

          -  Not known when last two DOAC doses were administered prior to blood draw

          -  DOAC first administered (or resumed after temporary cessation) less than 7 days prior
             to blood draw

          -  DOAC dosage outside of manufacturer's recommended range (e.g. study subject with
             renal impairment and supratherapeutic dose)

          -  Heparin or LMWH administered within 7 days prior to blood draw

          -  On any medications known to affect coagulation status and listed below

          -  Bruising, wounds or scarring in the area of venipuncture

        List of medications known to affect coagulation status

          1. Vitamin K Antagonists [VKAs] Warfarin Phenprocoumon Acenocoumarol Tecarfarin
             [ATI-5923] Phenindione Anisindione Elinogrel Vorapaxar Atopaxar

          2. Heparin and Heparins Unfractionated Heparin [UFH] LMWH Fondaparinux Idraparinux
             Danaparoid

          3. Vasopressin Analogues DDAVP

          4. Direct Thrombin [IIa] Inhibitors Hirudin Lepirudin Bivalirudin Argatroban

          5. Defibrinating Agents Ancrod
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Memorial Hospital South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Greve</last_name>
      <phone>574-647-7459</phone>
    </contact>
    <investigator>
      <last_name>Mark Walsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Institute of Rural Health</name>
      <address>
        <city>Deluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Leone</last_name>
      <phone>218-786-4869</phone>
    </contact>
    <investigator>
      <last_name>Ramin Artang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Healthcare System</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Robinson</last_name>
      <phone>864-560-1046</phone>
      <email>krobinson@gibbscc.org</email>
    </contact>
    <contact_backup>
      <last_name>Heather Farmer</last_name>
      <phone>864-560-1060</phone>
      <email>hfarmer@gibbscc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Thurston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Health Care Services</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Bliden</last_name>
      <phone>703-776-3855</phone>
    </contact>
    <contact_backup>
      <last_name>Kathleen Morgan</last_name>
      <phone>703-335-8750</phone>
      <email>Kathleen.Morgan@inova.org</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Gurbel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>June 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
